enm-2024-2164-Supplemental-Fig-S1.pdf Supplemental Fig
Moreover, the SURMOUNTMMO (tirzepatide, NCT05556512) will assess the impact of the dual GLP-1/GIP RA in cardiovascular outcomes and all-cause mortality for people with obesity (without diabetes) when the REDEFINE-3 study will assess the impact of cagrisema in people with obesity (with and without T2DM) and established cardiovascular disease
However, rapid weight loss often comes with unwanted side effects: muscle loss (up to 20-60% of total weight lost) and sagging skin on areas like the arms, neck, or belly
Many products are not compounds tested in human clinical trials with an eight-digit Health Canada Drug Identification Number or controlled substances like anabolic steroids
But "any time" does not mean "all times are equal." It means the manufacturer did not find a statistically significant difference in primary endpoints based on timing in their pivotal trials
User agrees and understands that the use of the Website is for individuals only and is prohibited from use by non-individuals or their agents, attorneys, or attorney representatives
